What the Study Found (In Plain English)
Published in Indian journal of dermatology, venereology and leprology (2009), this randomized controlled trial evaluating human clinical outcomes investigated: Finasteride, a type II-selective 5alpha-reductase inhibitor, as a causative agent of decreasing dihydroxy testosterone (DHT) level, is effective in the treatment of male androgenic alopecia. Key clinical takeaway: The results of this study showed that the therapeutic effects of both finasteride gel and finasteride tablet were relatively similar to each other.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Indian journal of dermatology, venereology and leprology, 2009-01-15; Randomized Controlled Trial; Rigor 88/100): The results of this study showed that the therapeutic effects of both finasteride gel and finasteride tablet were relatively similar to each other.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.